“…These changes may be mediated by a direct action of famotidine on hepatic H2 receptors [14] which could regulate, at least in part, IL-6-induced APP synthesis, and by a lower hepatic IL-1 receptor expression induced by naproxen, as has been seen in synovial cells and chondrocytes [22,23]. In addition, results from experimental research suggest that granular products of mast cells, espe-371 cially histamine, are involved in both acute and chronic inflammation affecting implanted biomaterial and that simultaneous administration of histamine H1 and H2 receptor antagonists (pyralamine and famotidine, respectively), greatly diminishes histamine effects [30].…”